izpis_h1_title_alt

Algorithmically deduced FREM2 molecular pathway is a potent grade and survival biomarker of human gliomas
ID Zolotovskaia, Marianna (Avtor), ID Zottel, Alja (Avtor), ID Šamec, Neja (Avtor), ID Jovchevska, Ivana (Avtor), et al.

.pdfPDF - Predstavitvena datoteka, prenos (4,76 MB)
MD5: 6C2D8E8EB22781D21EE9D98613C60CD0
URLURL - Izvorni URL, za dostop obiščite https://www.mdpi.com/2072-6694/13/16/4117 Povezava se odpre v novem oknu

Izvleček
Gliomas are the most common malignant brain tumors with high mortality rates. Recently we showed that the FREM2 gene has a role in glioblastoma progression. Here we reconstructed the FREM2 molecular pathway using the human interactome model. We assessed the biomarker capacity of FREM2 expression and its pathway as the overall survival (OS) and progression-free survival (PFS) biomarkers. To this end, we used three literature and one experimental RNA sequencing datasets collectively covering 566 glioblastomas (GBM) and 1097 low-grade gliomas (LGG). The activation level of deduced FREM2 pathway showed strong biomarker characteristics and significantly outperformed the FREM2 expression level itself. For all relevant datasets, it could robustly discriminate GBM and LGG (p < 1.63 × 10$^{−13}$, AUC > 0.74). High FREM2 pathway activation level was associated with poor OS in LGG (p < 0.001), and low PFS in LGG (p < 0.001) and GBM (p < 0.05). FREM2 pathway activation level was poor prognosis biomarker for OS (p < 0.05) and PFS (p < 0.05) in LGG with IDH mutation, for PFS in LGG with wild type IDH (p < 0.001) and mutant IDH with 1p/19q codeletion (p < 0.05), in GBM with unmethylated MGMT (p < 0.05), and in GBM with wild type IDH (p < 0.05). Thus, we conclude that the activation level of the FREM2 pathway is a potent new-generation diagnostic and prognostic biomarker for multiple molecular subtypes of GBM and LGG.

Jezik:Angleški jezik
Ključne besede:glioma, glioblastoma, survival prognosis, FREM2, algorithmically deduced molecular pathway, transcriptomics
Vrsta gradiva:Članek v reviji
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:MF - Medicinska fakulteta
Status publikacije:Objavljeno
Različica publikacije:Objavljena publikacija
Leto izida:2021
Št. strani:21 str.
Številčenje:Vol. 13, iss. 16, art. 4117
PID:20.500.12556/RUL-135973 Povezava se odpre v novem oknu
UDK:616-006
ISSN pri članku:2072-6694
DOI:10.3390/cancers13164117 Povezava se odpre v novem oknu
COBISS.SI-ID:73102083 Povezava se odpre v novem oknu
Datum objave v RUL:05.04.2022
Število ogledov:455
Število prenosov:86
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
:
Kopiraj citat
Objavi na:Bookmark and Share

Gradivo je del revije

Naslov:Cancers
Skrajšan naslov:Cancers
Založnik:MDPI
ISSN:2072-6694
COBISS.SI-ID:517914137 Povezava se odpre v novem oknu

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Začetek licenciranja:16.08.2021

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:gliom, glioblastom, napoved preživetja

Projekti

Financer:EC - European Commission
Program financ.:ERA-NET EuroTransBio

Financer:Drugi - Drug financer ali več financerjev
Program financ.:Federal Ministry of Education and Research (BMBF)
Akronim:OMICSGLIOMA

Financer:EC - European Commission
Program financ.:ERA-NET RUS Plus
Akronim:GOTICS

Financer:ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:Z3-1869
Naslov:Razvoj anti-FREM2 nanotelesa in njegova uporaba pri ciljanju glioblastomskih celic

Financer:Drugi - Drug financer ali več financerjev
Program financ.:Russian Foundation for Basic Research
Številka projekta:20-515-76007

Podobna dela

Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:

Nazaj